# Emergent BioSolutions Inc.: Form 10-K for the period ended Dec 31, 2015

- Company: [Emergent BioSolutions Inc.](/companies/ebs.md) (CIK 1367644)
- Form: 10-K
- Filed: 2016-02-29
- Accepted by EDGAR: Feb 29, 2016, 14:31 ET
- Period: 2015-12-31
- Accession: 0001367644-16-000059
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1367644/000136764416000059/form10-k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1367644/000136764416000059/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-10-01 to 2015-12-31 | $168.1m | us-gaap:SalesRevenueNet |
| Revenue | 12 months, 2015-01-01 to 2015-12-31 | $522.8m | us-gaap:Revenues |
| Cost of revenue | 12 months, 2015-01-01 to 2015-12-31 | $124.3m | us-gaap:CostOfGoodsSold |
| Research and development | 12 months, 2015-01-01 to 2015-12-31 | $154.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2015-01-01 to 2015-12-31 | $148.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-10-01 to 2015-12-31 | $49.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months, 2015-01-01 to 2015-12-31 | $96.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months, 2015-01-01 to 2015-12-31 | $6.5m | us-gaap:InterestExpense |
| Income tax | 12 months, 2015-01-01 to 2015-12-31 | $26.9m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-10-01 to 2015-12-31 | $33.3m | us-gaap:NetIncomeLoss |
| Net income | 12 months, 2015-01-01 to 2015-12-31 | $62.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-10-01 to 2015-12-31 | $0.71 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months, 2015-01-01 to 2015-12-31 | $1.41 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-10-01 to 2015-12-31 | $0.85 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months, 2015-01-01 to 2015-12-31 | $1.63 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2015-01-01 to 2015-12-31 | 47,255,842 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months, 2015-01-01 to 2015-12-31 | $44.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months, 2015-01-01 to 2015-12-31 | $100.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2015-12-31 | $312.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-12-31 | $538.6m | us-gaap:AssetsCurrent |
| Total assets | at 2015-12-31 | $1.04bn | us-gaap:Assets |
| Current liabilities | at 2015-12-31 | $99.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-12-31 | $383.6m | us-gaap:Liabilities |
| Long-term debt | at 2015-12-31 | $253.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2015-12-31 | $660.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1367644/000136764416000059/form10-k.htm

Filed Feb 29, 2016.
Source: SEC EDGAR, the filing index for accession 0001367644-16-000059. Last ingested by Listed: Nov 4, 2026, 16:51 ET. No prices; not investment advice.
